4 Results for "

KRAS G13D mutations

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "KRAS G13D mutations" in MCE Product Catalog:

Cat. No.: HY-176489
CAS No.: 3043908-63-7
Target:  

PROTACs Ras

Research Areas:  

Cancer

PROTAC pan-KRAS degrader-1 is a pan-KRAS PROTAC degrader for degrading different KRAS mutation types, such as G12D, G12C, G12V, and G13D. PROTAC pan-KRAS degrader-1 potently degrades KRAS mutation (G12D) in AGS cells, with a DC50 of 1.1 nM, Dmax of 95%. PROTAC pan-KRAS degrader-1 can be used to search diseases caused by KRAS mutation or amplification, especially cancers such as breast cancer, bladder cancer, gastric cancer, etc .
loading...
    loading...
Cat. No.: HY-P3129
CAS No.: 145019-94-9
Target:  

Ras

Research Areas:  

Inflammation/Immunology Cancer

KRAS G13D peptide, 25 mer, a KRAS activating oncogene mutation peptide, is an immune potentiator extracted from patent WO2018144775A1. KRAS G13D peptide, 25 mer can be used to prepare KRAS vaccine .
loading...
    loading...
Cat. No.: HY-181704
CAS No.: 3084918-70-4
Target:  

PERK Ras

Research Areas:  

Cancer

KRAS-IN-54 is a macrocyclic KRAS inhibitor. KRAS-IN-54 exhibits activity against cell viability and pERK inhibition in cells with KRAS G12D and KRAS G13D mutations. KRAS-IN-54 can be used in the research of KRAS-mutant cancers, including pancreatic adenocarcinoma, colorectal cancer, non-small cell lung cancer, esophageal cancer, gallbladder cancer, melanoma, ovarian cancer and endometrial cancer .
loading...
    loading...
Cat. No.: HY-183553
CAS No.: 2874214-01-2
Target:  

Ras

Research Areas:  

Cancer

AUBE00 is an orally active, selective cyclic peptide pan-KRAS inhibitor. AUBE00 selectively binds to the OFF state of KRAS. AUBE00 exhibits anticancer activity against RAS wild-type colorectal cancer. The combination of AUBE00 with Cetuximab (HY-P9905) produces a synergistic antiproliferative effect .
loading...
    loading...